Company intelligence / Profile preview

Exciton Technologies

Edmonton, Alberta, Canadaexcitontech.com ↗

Ownership: Private
Employees: ~18
Development stage: Commercial

Overview

Exciton Technologies has developed proprietary silver oxysalt-based wound dressings demonstrating superior antibacterial activity at lower cost compared to conventional silver dressings. Their products are commercially available and evidence of improved patient outcomes with their advanced antimicrobial properties continues to grow globally.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Device (wound dressing)Antimicrobial barrier (silver-based)Advanced material (silver oxysalts technology)
Industry: Consumable Medical Devices

Drug pipeline

2 assets

exsalt SD7

Commercial

Indications: Wound infection, Diabetic foot ulcer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Exciton Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exciton Technologies.

Explore the full profile